TransMedics Group, Inc. — Form 8-K Summary
Business Context and Reporting Period
TransMedics Group, Inc. filed a Current Report on Form 8-K dated February 27, 2020, signed February 28, 2020. The filing reports an amendment to the company’s credit agreement and a change in its fiscal year-end. The company is an emerging growth company, and its common stock trades on Nasdaq under the symbol TMDX.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt balance, liquidity, or other operating financial metrics.
Material Changes
- On February 27, 2020, the company entered into an amendment to the June 22, 2018 Credit Agreement among TransMedics, Inc. as borrower, TransMedics Group, Inc., TransMedics, B.V., and OrbiMed Royalty Opportunities II, LP as lender.
- The amendment defines a fiscal quarter as a quarter ending March 31, June 30, September 30, or December 31, and defines the fiscal year as the year ending December 31.
- The board approved changing the company’s fiscal year-end from the last Saturday in December to December 31. The current fiscal year will end on December 31, 2020.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, operating outlook, management commentary, risk discussion, or contingency amounts. The principal unusual items are the credit agreement amendment and the fiscal year-end change. The filing states that the credit agreement summary is qualified in its entirety by the full amendment filed as Exhibit 10.1.
Investor Verification Items
- Review Exhibit 10.1 for the complete terms and any financial, covenant, maturity, or other effects of the credit agreement amendment.
- Confirm the transition and comparative reporting implications of the change to a December 31 fiscal year-end.
- Obtain subsequent filings for financial results, debt balances, liquidity, and any updated guidance or risk disclosures.